These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 32702178)

  • 1. Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis.
    Trinh VQ; Shi C; Ma C
    Histopathology; 2020 Dec; 77(6):865-876. PubMed ID: 32702178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship?
    McCarthy DM
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions.
    Song H; Zhu J; Lu D
    Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010623. PubMed ID: 25464111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Subtype classification and clinicopathological characteristics of gastric neuroendocrine neoplasms: an analysis of 241 cases].
    Zhang P; Zhang Y; Zhang C; Shi Y; Liu J; Liu Q; Yu L; Wang M; Zou G; Lou J; Chen J; Tan H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1241-1246. PubMed ID: 27928793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of hypergastrinemia secondary to long-term proton pump inhibitor treatment on ECL cell tumorigenesis in human gastric mucosa.
    Tatsuguchi A; Hoshino S; Kawami N; Gudis K; Nomura T; Shimizu A; Iwakiri K
    Pathol Res Pract; 2020 Oct; 216(10):153113. PubMed ID: 32853950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and treatment of gastric neuroendocrine tumours.
    Plöckinger U
    Wien Klin Wochenschr; 2007; 119(19-20):570-2. PubMed ID: 17985089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Proton Pump Inhibitors on the Development of Gastric Neoplastic Lesions in Patients With Autoimmune Atrophic Gastritis.
    Dilaghi E; Bellisario M; Esposito G; Carabotti M; Annibale B; Lahner E
    Front Immunol; 2022; 13():910077. PubMed ID: 35935934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of gastric enterochromaffin-like cells growth in Zollinger-Ellison syndrome and atrophic body gastritis patients.
    Delle Fave G; Marignani M; Corleto VD; Angeletti S; D'Ambra G; Ferraro G; D'Adda T; Azzoni C; Jensen RT; Annibale B; Bordi C
    Dig Liver Dis; 2002 Apr; 34(4):270-8. PubMed ID: 12038811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors related to gastric neuroendocrine tumors.
    Soto-Solís R; Romano-Munive AF; Santana de Anda K; Barreto-Zuñiga R
    Rev Gastroenterol Mex (Engl Ed); 2019; 84(1):52-56. PubMed ID: 29705524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enterochromaffin-like Cell Hyperplasia-Associated Gastric Neuroendocrine Tumors May Arise in the Setting of Proton Pump Inhibitor Use.
    Rais R; Trikalinos NA; Liu J; Chatterjee D
    Arch Pathol Lab Med; 2022 Mar; 146(3):366-371. PubMed ID: 34283890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology.
    Lundell L; Vieth M; Gibson F; Nagy P; Kahrilas PJ
    Aliment Pharmacol Ther; 2015 Sep; 42(6):649-63. PubMed ID: 26177572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton Pump Inhibitor Induction of Gastric Cobblestone-like Lesions in the Stomach.
    Takahari K; Haruma K; Ohtani H; Kiyoto S; Watanabe A; Kamada T; Manabe N; Hatano Y
    Intern Med; 2017 Oct; 56(20):2699-2703. PubMed ID: 28924108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence?
    Cavalcoli F; Zilli A; Conte D; Ciafardini C; Massironi S
    Scand J Gastroenterol; 2015; 50(11):1397-403. PubMed ID: 26059834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastric carcinoids after long-term use of a proton pump inhibitor.
    Jianu CS; Fossmark R; Viset T; Qvigstad G; Sørdal O; Mårvik R; Waldum HL
    Aliment Pharmacol Ther; 2012 Oct; 36(7):644-9. PubMed ID: 22861200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histologic changes in type A chronic atrophic gastritis indicating increased risk of neuroendocrine tumor development: the predictive role of dysplastic and severely hyperplastic enterochromaffin-like cell lesions.
    Vanoli A; La Rosa S; Luinetti O; Klersy C; Manca R; Alvisi C; Rossi S; Trespi E; Zangrandi A; Sessa F; Capella C; Solcia E
    Hum Pathol; 2013 Sep; 44(9):1827-37. PubMed ID: 23642738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endoscopic findings of the gastric mucosa during long-term use of proton pump inhibitor - a multicenter study.
    Kiso M; Ito M; Boda T; Kotachi T; Masuda K; Hata K; Sasaki A; Kawamura T; Yoshihara M; Tanaka S; Chayama K
    Scand J Gastroenterol; 2017 Aug; 52(8):828-832. PubMed ID: 28485638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.
    Moore AR; Boyce M; Steele IA; Campbell F; Varro A; Pritchard DM
    PLoS One; 2013; 8(10):e76462. PubMed ID: 24098507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study.
    Campana D; Ravizza D; Ferolla P; Faggiano A; Grimaldi F; Albertelli M; Ricci C; Santini D; Brighi N; Fazio N; Colao A; Ferone D; Tomassetti P
    Endocrine; 2017 Jun; 56(3):633-638. PubMed ID: 27592118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of proton pump inhibitors and risk of gastric cancers: review of literature and pathophysiological mechanisms.
    Ko Y; Tang J; Sanagapalli S; Kim BS; Leong RW
    Expert Opin Drug Saf; 2016 Jan; 15(1):53-63. PubMed ID: 26560097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.
    Jensen RT
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):4-19. PubMed ID: 16433886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.